RNAi-Induced Expression of Paternal UBE3A

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Angelman syndrome is a neurodevelopmental disorder caused by deficiency of the maternally inherited UBE3A gene.
• In mature neurons, paternal UBE3A allele is silenced by the UBE3A antisense transcript (UBE3A-ATS).
• Strategies to activate paternal UBE3A expression are crucial for therapeutic development.

Purpose of the Study:

• To investigate the downregulation of UBE3A-ATS using RNA interference (RNAi).
• To assess the activation of paternal UBE3A expression in mouse and human neurons.
• To evaluate the impact on Angelman syndrome-related genes.

Main Methods:

• Utilized small interfering RNA (siRNA) and lentiviral short hairpin RNA (LV-shRNA) targeting SNORD115.
• Administered RNAi to suppress UBE3A-ATS expression in mouse primary neurons and human iPSC-derived neurons.
• Assessed UBE3A and related gene expression at transcript and protein levels.

Main Results:

• siRNA and LV-shRNA targeting SNORD115 reduced UBE3A-ATS expression.
• Observed activation of paternal UBE3A RNA and protein expression in both mouse and human neurons.
• Similar effects were noted in different genetic backgrounds of mouse neurons.

Conclusions:

• shRNA-mediated inhibition of UBE3A-ATS by targeting SNORD115 effectively restores UBE3A expression.
• This approach shows promise for Angelman syndrome treatment in neuronal cells.
• Further in vivo evaluation is needed to assess translational applicability and potential off-target effects.